Datamonitor analysis has identified two key company categories currently shaping the
biotech industry: the leading biotherapeutics players and the emerging biotherapeutics …

Pharmaceutical companies are facing several major interrelated challenges, the most
strategic being the decline in R&D productivity resulting in empty product pipelines to …

Ten years ago a brief chapter such as this would have chronicled the fi-nancing aspects of
the biotechnology industry—the life cycle of a “typi-cal” biotechnology company. For a …

A study was undertaken that validates the business models of biotechnology companies that
compete in the pharmaceutical marketplace. Strategic alliances, largely with established …

This case describes Anne Evans' search for a market opportunity in the biotechnology
industry, and examines the feasibility of establishing a new venture to exploit this …

There are multiple options or paths to the market to be considered when developing the
commercialization strategy for translating a technology or invention into an innovation. We …

Abstract Development of a product is the key focus of all biotechnology companies. Detailed
and accurate planning of the development pathway is vital for success. In this chapter, we …

When we published the first Bioentrepreneurship supplement in May 1998, we asked a
select group of biotechnology and pharmaceutical executives, investment bankers, venture …

The ever-increasing size of drug companies resulting from continuing merger activity is
giving rise to unprecedented R&D budgets. During the 1980s, an R&D budget of $1 billion …

Much like the biological systems it explores, the US biotechnology industry has mechanisms
that allow it to change in response to its environment. Terms such as 'consolidation',' …